Krüppel-like factor 4 (KLF4) functions as a tumor suppressor in some cancers, but its molecular mechanism is not clear. Our recent study also showed that the expression of KLF4 is dramatically reduced in primary lung cancer tissues. To investigate the possible role of KLF4 in lung cancer, we stably transfected KLF4 into cells from lung cancer cell lines h322 and A549 to determine the cells' invasion ability. Our results showed that ectopic expression of KLF4 extensively suppressed lung cancer cell invasion in Matrigel. This effect was independent of KLF4-mediated p21 upregulation because ectopic expression of p21 had minimal effect on cell invasion. Our analysis of the expression of 12 genes associated with cell invasion in parental, vector-transfected and KLF4-transfected cells showed that ectopic expression of KLF4 resulted in extensively repressed expression of secreted protein acidic and rich in cysteine (sPARC), an extracellular matrix protein that plays a role in tumor development and metastasis. Knockdown of sPARC expression in h322 and A549 cells led to suppression of cell invasion, comparable to that observed in KLF4-transfected cells. Moreover, retrovirusmediated restoration of sPARC expression in KLF4-transfected cells abrogated KLF4-induced anti-invasion activity. Together, our results indicate that KLF4 inhibits lung cancer cell invasion by suppressing sPARC gene expression.
to induce apoptosis in ovarian cancer 23 but to inhibit metastasis in some breast cancer cells. 24 Thus, the role of SPARC in tumor progression and invasion may be dependent on tissue type or cell context. Nevertheless, little is known about the regulation of SPARC expression in normal and tumor tissues.
As seen with SPARC, altered expression of Krüppel-like factor 4 (KLF4) has been reported in various cancers, and downregulation of KLF4 has been associated with cancer development, progression and metastasis. 25, 26 KLF4, a SP1-like zinc finger transcriptional factor, 27 has been reported to play an important role in stem cells. 28 Our recent study showed that KLF4 may function as a tumor-suppressive gene in lung cancer because expression of KLF4 is downregulated in a substantial number of primary lung cancers and because ectopic expression of KLF4 suppressed lung cancer cell proliferation and clonogenic formation in vitro. Moreover, enforced expression of KLF4 in lung cancer cells by ex vivo transfection or by adenovector-mediated gene transfer suppressed tumor growth in vivo. 29 However, the molecule mechanisms underlying KLF4's tumor-suppressive function in lung cancer remain to be determined.
To further explore the possible role of KLF4 in lung cancer, we analyzed lung cancer cell invasion with or without ectopic expression of KLF4. Our results showed that ectopic expression of KLF4 extensively suppressed lung cancer invasion and that this anti-invasion effect was not caused by upregulation
Introduction
Secreted protein acidic and rich in cysteine (SPARC, also named osteonectin or BM40) is an extracellular matrix protein that binds selectively to collagen fibrils and minerals and plays an important role in bone calcification. 1 A growing body of evidence has shown that SPARC also plays a role in tumor development and metastasis. Overexpression of SPARC has been associated with the progression of, and poor outcome in, various cancers, including melanoma, 2 glioma, 3, 4 cancers of the breast, 5, 6 prostate, 7 liver, 8 pancreas, 9 bladder, 10 head and neck 11, 12 and lung. 13 Molecular characterization has revealed that SPARC can suppress E-cadherin expression, induce mesenchymal transition, and promote tumor cell invasion and metastasis. [14] [15] [16] It can also promote cell survival by activating AKT, focal adhesion kinase and/or integrin-linked kinase. 17, 18 In addition, SPARCderived peptides may play a role in angiogenesis. 19 Suppression of SPARC expression by a SPARC antisense expression vector suppressed in vitro adhesive and invasive capacities of melanoma cells and completely abolished their in vivo tumorigenicity. 20 These observations collectively indicated that SPARC plays a critical role in invasive/metastatic phenotype in various tumors. However, controversial results associated with both the overexpression and underexpression of SPARC have been reported in colorectal cancer. 21, 22 SPARC has also been found KLF4-mediated anti-invasion activity is independent of p21 upregulation. KLF4 is known to activate p21(WAF1/Cip1) through a specific Sp1-like cis-element in the p21(WAF1/Cip1) proximal promoter. 31 Our recent studies also revealed that ectopic expression of KLF4 in lung cancer cells upregulated p21 expression. 29 To test whether KLF4-mediated anti-invasion activity is associated with upregulation of p21 and consequent cell cycle arrest at G 1 phase, we established H322 and A549 cells stably overexpressing p21 and evaluated their in vitro invasion ability. Western blot analysis revealed that H322 and A549 cells transfected with KLF4 and p21 had equivalent levels of p21 expression ( Fig. 2A) . Nevertheless, an in vitro Matrigel cell-invasion assay showed that ectopic expression of p21 in H322 and A549 cells, compared with that in parental and empty vector-transfected cells, had no obvious effect on cell invasion (p > 0.05) ( Fig. 2B and C) . These results indicated that KLF4-mediated anti-invasion activity was not associated with the upregulation of p21 expression in lung cancer.
Ectopic expression of KLF4 leads to extensive downregulation of SPARC. To further investigate the mechanisms underlying KLF4-induced anti-invasion activity, we analyzed the expression of various genes that were reported to play roles in cancer cell invasion, 32, 33 including MMP1, MMP9, SPARC, TERT, PKLR, IL3RA, IGF1, VEGFA, RHOC, TGFB1, PLAU and VCAM1. [28] [29] [30] [31] [32] [33] [34] For this purpose, we isolated total RNA and determined mRNA levels in these genes in parental, vectortransfected, and KLF4-transfected H322 and A549 cells by using real-time PCR. The housekeeping gene ACTB (also know as β-actin) was used as the internal reference gene to control mRNA quantity. As expected, cells transfected with KLF4 had higher levels of KLF4 mRNA than did parental or vector control cells. For most genes tested, ectopic expression of KLF4 did not lead to extensive changes at mRNA levels. Of interest, of p21, a cell cycle regulator whose expression is regulated by KLF4, 30 because ectopic expression of p21 had no effect on lung cancer invasion. Analysis of several genes involved in cell invasion revealed that ectopic expression of KLF4 led to a drastic suppression of SPARC gene expression, suggesting that KLF4 suppresses lung cancer cell invasion by suppressing SPARC expression.
Results

Enforced expression of KLF4-suppressed lung cell invasion.
We recently found that ectopic expression of KLF4 resulted in marked inhibition of lung cancer cell growth and clonogenic formation and that knockdown of KLF4 promoted cell growth in immortalized human bronchial epithelial cells. 29 To further explore the biologic function of the KLF4 gene in lung cancer cells, we determined the extent of lung cancer cell invasion after retrovirus-mediated KLF4 gene transfer. H322 and A549 cells were infected with retrovirus expressing KLF4 or a control vector and selected with geneticin. The parental, KLF4-transfected, or control vector-transfected H322 and A549 cells were then analyzed for their ability to invade a Matrigel-coated membrane. The results showed that ectopic expression of KLF4 in H322 and A549 cells, compared with that of parental and control vector-transformed cells, significantly suppressed cell invasion (p < 0.01) (Fig. 1) . This suppression of cell invasion is unlikely caused by KLF4-mediated cell growth inhibition because KLF4 stably transfected cells had similar growth rate as parental cells when tested at 24-72 h after cell seeding, although those cells had dramatically reduced clonogenic formation ability when compared with parental cells at a relatively long-term cell culture (9 d). This result indicated that KLF4 is critical in lung cancer cell invasion. a substantial reduction in mRNA levels was observed for SPARC in both KLF4-transfected H322 and A549 cells, compared with levels in parental and vector-transfected cells ( Table 1) . This result was confirmed by protein analysis. SPARC expression was easily detectable in parental and vector-transfected cells but was completely abolished in KLF4-transfected cells (Fig. 3) . These results indicated that expression of SPARC is regulated by KLF4 in lung cancer cells.
Knockdown of SPARC inhibited cell invasion in vitro. SPARC, also known as osteonectin, is an extracellular matrix protein that plays an important role in the calcification of bone. 1 It is reported to promote cancer cell invasion and migration in glioma and prostate cancer.
4,34 SPARC overexpression is often associated with the most aggressive and highly metastatic tumors. 35 To investigate whether downregulation of SPARC alters cell invasion activity in human lung cancer, we inhibited SPARC expression in H322 and A549 cells by using SPARC-specific siRNA. Transfection with SPARC siRNA markedly inhibited the expression of SPARC protein in both H322 and A549 cells compared with the expression seen when control siRNA and mock-treated cells were used (Fig. 4A) . Cell viability in H322 and A549 cells was determined after treatment with SPARC siRNA or control siRNA, and results showed that knockdown of SPARC did not affect cell viability compared with viability in parental-and control siRNA-treated cells (data not shown). Nevertheless, in vitro cell invasion analysis performed on Matrigel showed that knockdown of SPARC extensively suppressed cell invasion in both H322 and A549 cells, compared with cells treated with control siRNA or phosphate-buffered saline (PBS) (parental cells) (Fig. 4B) . These results, like those observed in glioma and prostate cancer, suggested that SPARC plays an important role in cell migration and invasion in lung cancer cells.
Enforced expression of SPARC restores KLF4-mediated inhibition of cell invasion. To further determine the role of SPARC in KLF4-mediated anti-invasion activity, we introduced SPARC cDNA via retrovirus-mediated gene transfer to H322 and A549 cells stably transfected with KLF4. A retrovirus expressing the GAPDH gene was used as a vector control. The 
Discussion
Our results demonstrated that ectopic expression of KLF4 inhibited lung cancer cell invasion in vitro and that KLF4-mediated anti-invasion activity is caused by inhibition of SPARC gene expression. The role of the SPARC gene in cancer cell invasion and cancer metastasis has been studied by several groups, and accumulating evidence has shown that SPARC promotes cancer cell invasion and metastasis in glioma, melanoma and prostate cancer. 4, 14, 34 Although the role of SPARC in lung cancer invasion and metastasis was not well characterized previously, SPARC had been extensively induced by treating bronchial epithelial cells with cigarette smoke condensate. 36 High levels of SPARC expression had been observed in the stroma of patients with non-small cell lung cancer 13, 36 and had been associated with nodal metastasis and poor prognosis 13 suggesting that SPARC may play a role in lung cancer cell invasion and metastasis. Our results showed that downregulation of SPARC, either by siRNA or by ectopic expression of KLF4, suppressed lung cancer cell invasion, providing direct evidence of the role of SPARC in lung cancer cell invasion.
Despite many reports about the association between SPARC gene expression and cancer progression, little is known about the regulation of SPARC expression. Aberrant SPARC promoter methylation has been reported in lung cancer and colon cancer. 37, 38 In contrast, c-Jun has been reported to induce SPARC in MCF7 breast cancer cells 39 but to suppress SPARC expression in rat embryo fibroblasts, 40 suggesting that transcriptional factors involved in SPARC regulation might be species-or cell typespecific. Our study showed that SPARC expression in lung cancer cells was extensively suppressed by ectopic expression of KLF4, which was found to be downregulated in lung cancer tissues, 29 thus, indicating that KLF4 is a negative regulator of SPARC in lung cancer.
Moreover, the apparent inhibitory effect of KLF4 on lung cancer cell invasion led us to test its effect on invasion-related genes. Among the 12 genes tested, SPARC was the only one that was extensively suppressed by KLF4 in both H322 and A549 cells. Knockdown of SPARC by siRNA also inhibited lung cancer cell invasion, as observed in KLF4 overexpression. Furthermore, restoration of SPARC expression in KLF4-transfected cells abrogated KLF4-mediated anti-invasion activity. Thus, SPARC is one of the major downstream molecules of KLF4-induced anti-invasion activity in lung cancer cells.
KLF4 is a zinc-finger transcription factor of the SP/KLF family of transcriptional factors, which includes three domains of Kruppel-like zinc fingers. All of the members of the SP/KLF family of transcriptional factors can recognize and specifically bind to GC-rich sequences 41 thereby regulating various target genes involved in differentiation, proliferation and apoptosis. Evidence has shown that KLF4 competes with SP1 in promoter binding and suppresses the expression of SP1-regulated genes such as cyclin D1 and ornithine decarboxylase. 42, 43 Whether KLF4 regulates SPARC through a similar mechanism remains to be determined, however, the SP1 consensus sequence was identified in the SPARC promoter. 39, 44 The expression of KLF4 itself is SPARC retroviral vector effectively restored SPARC expression in KLF4-transfected H322 and A549 cells (Fig. 5A) . The in vitro Matrigel cell-invasion assay showed that restoration of SPARC expression in KLF4-transfected H322 and A549 cells restored the cells' invasion ability, similar to the results seen in parental H322 and A549 cells (Fig. 5B) . These results indicated that KLF4-induced suppression of SPARC expression is critical for KLF4-mediated inhibition of lung cancer cell invasion. Cell-invasion assay. The Matrigel-based in vitro cell-invasion assay was performed by using a Falcon cell culture insert with reconstituted basement membrane matrix (Matrigel, Becton-Dickinson Biosciences, NJ). Cells suspended in DMEM containing 1% FBS were seeded onto the upper sides of insert filters coated with Matrigel (60 µg/insert) at a density of 1 x 10 5 cells/insert. The lower compartment of the Falcon 24-well plates contained 600 µL of DMEM medium with 10% FBS and 5 µg/mL fibronectin. After 24-48 h at 37°C under the regular culture condition, the noninvading cells on the upper side of the chamber membranes were removed with a cotton swab. The lower surfaces of the culture inserts were fixed with 5% glutaraldehyde and stained with 5% Giemsa. The number of invading cells on the opposite side of the chamber membranes was counted on each of three transwells.
Cell-viability assay. Cell viability was determined by using the sulforhodamine B assay, as described previously. 50 In brief, 3 x 10 3 cells were seeded in each well of 96-well flat-bottom plates and incubated for 24 h. Next, SPARC siRNA and control siRNA were transfected, as described below. At 72 h after incubation, 70 µL of 0.4% sulforhodamine B (w/v) in 1% acetic acid solution was added to each well and incubated at room temperature for an additional 60 min. The culture medium was removed, bound sulforhodamine B was solubilized with 100-200 µL of 10 mM unbuffered Tris-base solution (pH, 10.5), and absorbance was read on a multidetection microplate reader (Synergy HT, BIO-TEK Instruments, Inc., Winooski, VT) at 570 nm. Relative cell viability was determined by setting the viability of the control cells at 100% and comparing the viability of the treated cells with that of the controls. Each experiment was performed in quadruplicate and repeated at least twice.
Gene knockdown with siRNA. The siRNA for human SPARC coding sequence (GenBank accession No. NM_003118) was obtained from Dharmacon Research, Inc., (Chicago, IL). The forward and reverse RNA strands were CGA UGU UGU CAA frequently lost in various human cancer types, such as gastric, 25 colorectal, 45 esophageal squamous cell, 46 intestinal, 47 prostate, 48 bladder 49 and lung cancers; 29 of interest, SPARC was reportedly overexpressed in many of these cancers. Whether increased expression of SPARC in these cancers is caused by loss of KLF4 function is not clear. Nevertheless, our results showed that at least in some lung cancer cells, SPARC expression is negatively regulated by KLF4 and that KLF4 may execute its anti-invasion function by suppressing SPARC expression.
Materials and Methods
Human lung cancer cell lines. Lung cancer cell lines A549 and H322 are maintained in our laboratory. They are routinely cultured in Dulbecco's Modified Eagle's Medium (DMEM) supplemented with 10% heat-inactivated fetal bovine serum (FBS) and antibiotics (penicillin G at 100 units/mL and streptomycin at 100 µg/mL) and incubated at 37°C under regular culture conditions of 100% humidity, 95% air and 5% CO 2 .
Retrovirus-mediated gene transfection. Plasmids containing coding sequences for KLF4, SPARC and P21 were obtained either from OriGene Technologies, Inc., (Rockville, MD) or from the American Type Culture Collection (Manassas, VA). The coding sequences were cloned to pBabe-based retrovirus plasmids with either puromycin or neomycin as a selection marker for mammalian cells. (Detailed cloning procedures and plasmid maps are available upon request). The plasmids were then transfected to 293/Phoenix cells by using FuGENE HD reagent (Roche Applied Science, Indianapolis, IN) according to the manufacturer's instructions. Retroviral vectors were collected from a culture medium of 293/Phoenix cells at 48-72 h after transfection and used to infect lung cancer cells. After selection with geneticin or puromycin (Invitrogen Corporation, Carlsbad, CA) for 2 w, the positive clones were further studied. used as internal reference gene) are available from Ziren Research LLC (www.zirenresearch.com) upon request.
Western blot analysis. Western blotting was performed as previously described 29 with antibodies for KLF4, P21, SPARC (Santa Cruz Biotechnology, CA) and β-actin (Sigma Co., St. Louis, MO).
Statistical analysis. Analysis of variance (ANOVA) was performed by using Statistica software (StatSoft, Tulsa, OK) for comparisons among groups. The Student's t test was used for comparison between two groups. A p value of <0.05 was considered statistically significant.
GGA UGG U dtdt and GCU ACA ACA GUU CCU ACC A dtdt, respectively. A control siRNA for random sequence UGA GAC CGA AGU UUU GGG U dtdt was also obtained from Dharmacon Research, Inc. For siRNA transfection, 10 µL of Lipofectamine 2000 (Invitrogen, San Diego) was mixed with 500 µL of Opti-MEM (Invitrogen, Carlbad) and then mixed with 200 pmol siRNA diluted in 500 µL of Opti-MEM. After incubation at room temperature for 20 min, the mixture was added to 60-mm plates with 5 mL of fresh medium. The cells were incubated at 37°C under regular conditions for indicated times before analysis.
Real-time absolute quantitative reverse transcriptasepolymerase chain reaction (real-time AqRT-PCR). Total RNA was extracted from cells using Trizol reagent (Invitrogen). 1 µg of RNA from each sample was reverse transcribed in a 20 µL reaction volume with use of the Taqman reverse transcription reagents (Applied Biosystems, Foster City, CA) according to the manufacturer's instructions. The cDNAs were diluted and quantified for expression of above given gene using real-time PCR (SYBR Green I) performed by Ziren Research LLC (Irvine, CA), with use of a single standard for getting the absolute ratio of each target and reference gene expressions, the procedure was performed as previously described. 33, 51 The primer sequences for KLF4, SPARC, MMP1, MMP9, TERT, PKLR, IL3RA, VEGFA, RHOC, TGFB1, IGF1, VCAM1, PLAU, ADAMTS1 and ACTB (β-actin
